ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

👍

ClearPoint Neuro EPS beats by $0.01, beats on revenue https://seekingalpha.com/news/3694800-clearpoint-neuro-eps-beats-0_01-beats-on-revenue • ClearPoint Neuro (NASDAQ:CLPT): Q1 GAAP EPS of -$0.13 beats by $0.01. • Revenue of $4.03M (+29.2% Y/Y) beats by $0.76M.

ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’ https://www.globenewswire.com/news-release/2021/05/11/2227629/25687/en/ClearPoint-Neuro-Reports-Record-Revenue-in-First-Quarter-2021-Results-Announces-FDA-Clearance-of-the-SmartFrame-Array.html

ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room https://www.globenewswire.com/news-release/2021/05/10/2226744/0/en/ClearPoint-Neuro-Announces-Partnership-With-D-K-Engineering-for-Development-of-Robotic-System-for-the-MRI-Suite-and-Operating-Room.html

dabei

ClearPoint Neuro: A Biotech Portfolio Play https://seekingalpha.com/article/4417555-clearpoint-neuro-biotech-portfolio-play Summary • Potential for 100 gene therapy trials to be using ClearPoint. • Expect significant growth in 2H 2021 as elective surgeries rebound and clinical trials restart. • Recent expansion to Europe augurs well for European biologics partners. • We see potential for $100M+ revenues and 30%+ net margins by 2025. ...

https://www.marketwatch.com/press-release/10-k-clearpoint-neuro-inc-2021-03-22

🍀

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results https://www.globenewswire.com/news-release/2021/03/04/2187587/0/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2020-Results.html Company Reports Record Revenues 2020 Full Year and Fourth Quarter Highlights • Reported fourth quarter 2020 revenue of $3.7 million, an increase of 16% compared with the fourth quarter of 2019. Reported revenue of $12.8 million for 2020, a 14% increase over 2019 and representing the sixth consecutive year of growth. • Increased biologics and drug delivery revenue to $5.0 million in 2020, a 109% increase over 2019, driven by service revenue. • Supported 682 cases in 2020 despite the continued challenges posed by the COVID-19 pandemic. • Completed a convertible note financing facility under which notes aggregating $25.0 million were issued, and ended 2020 with cash and cash equivalents totaling $20.1 million. ....

ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock http://www.globenewswire.com/news-release/2021/02/23/2180911/0/en/ClearPoint-Neuro-Announces-Closing-of-Public-Offering-of-2-127-660-Shares-of-Common-Stock.html

https://www.streetinsider.com/dr/news.php?id=18008226 Analyst Actions: B. Riley Raises ClearPoint Neuro's Price Target to $38 From $23, Keeps Buy Rating

ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips https://www.globenewswire.com/news-release/2021/02/18/2178484/0/en/ClearPoint-Neuro-Inc-Announces-License-and-Research-Agreement-with-Philips.html Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro Brain Model by 2022 ... Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock https://www.globenewswire.com/news-release/2021/02/19/2178608/0/en/ClearPoint-Neuro-Announces-Pricing-of-Public-Offering-of-1-850-140-Shares-of-Common-Stock.html ...announced today the pricing of its underwritten public offering of 1,850,140 shares of its common stock at a price to the public of $23.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 277,520 shares of its common stock at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on February 23, 2021, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to fund product development and research and development activities and the remainder for working capital and general corporate purposes.    ...

Absolut nachvollziehbar 😉

Man soll sich ja nicht in eine Aktie verlieben, aber hier wird’s schwierig...:D

ClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems https://www.globenewswire.com/news-release/2021/02/11/2174542/0/en/ClearPoint-Neuro-Inc-Announces-Multi-Product-Joint-Development-Option-Agreement-with-Blackrock-Microsystems.html Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets ...

Ich denke, dass einiges möglich ist, aber mag nicht spekulieren über Kurse.